Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.39 |
| ▸ | SRC | P12931 | 8/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16584539 | 0.90 | SRC (0.38) | SMYD2SRCJAK2JAK1ABCB1 | |
| SCHEMBL3387128 | 0.90 | SRC (0.38) | SMYD2SRCJAK2JAK1ABCB1 | |
| SCHEMBL13309095 | 0.90 | SRC (0.38) | SMYD2SRCJAK2JAK1ABCB1 | |
| SCHEMBL10121548 | 0.89 | SMYD2 (0.43) | SMYD2CYP3A4HTTSMN1; SMN2ABCB1 | |
| SCHEMBL29035279 | 0.83 | GPR119 (0.39) | SRCJAK2JAK1ABCB1GPR119 | |
| SCHEMBL12353638 | 0.79 | SMYD2 (0.39) | SMYD2CYP3A4HTTSMN1; SMN2ABCB1 | |
| SCHEMBL7870512 | 0.79 | SRC (0.37) | SRCJAK2JAK1ABCB1GPR119 | |
| SCHEMBL30493247 | 0.78 | NAMPT (0.47) | SMYD2JAK2JAK1CYP3A4HTT | |
| SCHEMBL2795827 | 0.78 | SMYD2 (0.36) | SMYD2JAK2JAK1CYP3A4HTT | |
| SCHEMBL14486195 | 0.78 | SMYD2 (0.36) | SMYD2JAK2JAK1CYP3A4HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040991-A1 | 3-AZABICYCLO [4.1.0] HEPTANES USED AS OREXIN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| US-20120040991-A1 | 3-AZABICYCLO [4.1.0] HEPTANES USED AS OREXIN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040991-A1 | 3-AZABICYCLO [4.1.0] HEPTANES USED AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, NPY2R | SMYD2 4026/4885SRC 4161/4885JAK2 4537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.